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Abstract
Background: Pseudotumors associated with metal-on-metal hips can be symptomatic or asymptomatic.
The purpose of this study was to identify the characteristics of pseudotumors associated with pain.
Methods: A total of 239 large-diameter, metal-on-metal total hip arthroplasties (THAs) were performed in
222 patients. Screening for pseudotumors was performed using magnetic resonance imaging (MRI) in all patients
who underwent metal-on-metal THA, and 57 patients with 62 affected hips showed pseudotumors. There were
45 women with 49 hips and 12 men with 13 hips affected, with a mean age of 64 years and a mean body mass
index (BMI) of 23.9 kg/m2. Sixteen hips had symptomatic pseudotumors with pain, and 46 hips were asymptomatic.
Pseudotumor size was determined. The anatomical position of pseudotumors was divided into anterior position
and posterolateral position. Types of pseudotumors were divided into two types: cystic type; and mixed solid cystic
and solid type without a cystic component. The follow-up study of pseudotumors was determined using MRI in
33 patients. The serum cobalt and chromium ion levels were measured in 38 patients after unilateral THA.
Univariate and multivariate analyses were performed comparing symptomatic and asymptomatic patients to
identify the characteristics of symptomatic pseudotumors.
Results: The mean BMI was 25.4 kg/m2 in symptomatic patients and 23.4 kg/m2 in asymptomatic patients; a higher
BMI was associated with symptoms (P = 0.036). Symptomatic pseudotumors were significantly larger (three-fold)
than asymptomatic pseudotumors (1812 mm2 vs 642 mm2, P = 0.003). Pseudotumors located in the anterior
position were associated with symptoms (P = 0.032), and mixed solid cystic and solid type pseudotumors were
associated with symptoms (P = 0.007). A multivariate analysis showed significant differences only in size (R2 = 0.298,
P = 0.031). No asymptomatic patients with pseudotumors became symptomatic during the follow-up period of MRI
evaluation.
Conclusion: Larger size was a significant factor for pain on multivariate analysis.
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Background
Pseudotumors associated with metal-on-metal hips are
common in resurfacing and total hip arthroplasty (THA).
Pseudotumors, including asymptomatic cases, have been
reported in up to 69 % of cases when patients are screened
after metal-on-metal hip resurfacing or THA [1–9]. Pseu-
dotumors can be asymptomatic or have a wide variation
in presentations, not only with pain and discomfort
in the groin, but also with cup loosening or nerve
palsy [2, 4, 5, 7, 8]. In addition, the prevalence of
pseudotumors was reported to be similar in well-
functioning patients and patients with painful metal-on-
metal hip implants [10]. Magnetic resonance imaging
(MRI) provides sensitive screening of pseudotumors fol-
lowing metal-on-metal hip implants. MRI is ideally suited
for assessment of these patients and complements stand-
ard clinical evaluation [11, 12].
It remains unclear whether asymptomatic patients
with pseudotumors become symptomatic and whether
* Correspondence: masahase@clin.medic.mie-u.ac.jp
Department of Orthopaedic Surgery, Mie University Graduate School of
Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507, Japan
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hasegawa et al. BMC Musculoskeletal Disorders  (2016) 17:456 
DOI 10.1186/s12891-016-1317-z
the presence of symptoms correlates with MRI findings
and patients’ characteristics. The purpose of this study
was to identify the factors associated with symptomatic
and asymptomatic pseudotumors. We hypothesized that
the pseudotumors would be larger in symptomatic pa-
tients and asymptomatic pseudotumors has specific fac-
tors not to become symptomatic.
Methods
A total of 239 large-diameter, metal-on-metal THAs
were performed in 222 patients. THA devices included
108 Cormet (Corin, Cirencester, UK), 80 Ultamet
(DePuy, Warsaw, IN), and 51 Conserve Plus (Wright
Medical Technology, Arlington, TN). Screening for
pseudotumors was performed using MRI after THA.
Pseudotumors were defined as any mass around the hip
joint. MRI studies were conducted in all subjects regard-
less of symptoms to ensure that asymptomatic pseudotu-
mors could be detected. The mean time at last follow-up
with MRI was 49 months (22–85 months). A 1.5-T scan-
ner was used with T1-weighted spin-echo (SE), T2-
weighted SE, and short tau inversion recovery (STIR) se-
quences (Signa; General Electric Healthcare, Waukesha,
WI, USA) (Table 1). An eight-channel cardiac coil (GE
Healthcare) was used. Two-dimensional fast spin echo
images were obtained using modifications to the pulse
parameters to reduce susceptibility artifact. A wider re-
ceiver bandwidth and oversampling in the frequency en-
coding axis were used to increase the strength of the
readout gradient [13].
Fifty-seven patients with 62 affected hips showed pseu-
dotumors (28 Cormet, 19 Ultamet, and 15 Conserve
Plus). There were 45 women with 49 hips and 12 men
with 13 hips, with a mean age of 64 years and a mean
body mass index (BMI) of 23.9 kg/m2. The primary diag-
noses were osteoarthritis in 54 patients and rheumatoid
arthritis in three patients. Sixteen hips had symptomatic
pseudotumors with pain, and 46 hips were asymptom-
atic. Fourteen of 16 symptomatic hips had undergone re-
vision surgery. Symptoms disappeared after revision in
all revised patients. The Cormet cup was made of
cobalt-chromium alloy with a titanium porous coating
for bone ingrowth. The Pinnacle cup, which was made
of titanium alloy, was a modular cup with a titanium
porous coating; a cobalt-chromium alloy liner was
inserted in the cup. The Conserve Plus cup was made of
a cobalt-chromium alloy with a cobalt-chromium alloy
bead coating. The head was made of cobalt-chromium
alloy in all implants. The mean head diameter of Cormet
devices was 43 mm (40–48 mm). The head diameter for
Pinnacle devices was 36 mm in all hips. The mean head
diameter of Conserve Plus devices was 47 mm (44–
52 mm). The acetabular component inclination angle
was measured on anteroposterior pelvic radiographs.
The inclination angle was defined as the angle between
the line joining the inferior teardrop points and the axis
of the opening of the acetabular component. Acetabular
anteversion was measured with computer software (Ad-
vanced CasePlan Digital Templating Planning Software,
Stryker Orthopedics, Mahwah, NJ) [14]. The mean in-
clination angle of the cup was 44° (23–70°), and the
mean anteversion angle was 14° (4–25°).
Pseudotumor size was determined on MRI by one in-
vestigator (MH), manually outlining the greatest axial
size of the mass. This investigator had 4 years of experi-
ence in MRI evaluation of postoperative hips. The area
of the pseudotumor was measured using computer soft-
ware (EV Insite Version 2.10.7.108; PSP Corporation,
Tokyo, Japan) (Fig. 1). The scan areas were obtained
from the same image for each longitudinal comparison.
The anatomical position of pseudotumors was divided
into anterior position and posterolateral position. When
both positions were involved, the hip was classified
based on the larger size. Pseudotumors were located in
the anterior position in 23 hips and in the posterolateral
position in 39 hips. Types of pseudotumors were divided
into two types [4, 15]: cystic type (35 hips) and mixed
solid cystic type and solid type without a cystic compo-
nent (27 hips) (Fig. 2). The follow-up study of pseudotu-
mors was determined using MRI in 33 patients. The
mean time between the first MRI and the follow-up MRI
was 24 months (8–66 months). Whether asymptomatic
Table 1 Pulse sequence protocol for MR imaging
Coronal T1 SE Coronal T2 SE Coronal STIR Axial T1 SE Axial STIR
Repetition time (msec) 450–560 3000–4090 5000–7600 450–500 5000–7600
Echo time (msec) 9–14 94–100 69–77 13–14 69–77
Inversion time (msec) 150 150
Receiver band-width (Hz per pixel) 300–400 300–400 300–400 300–400 300–400
Flip angle (degrees) 90 90 90 90 90
Field of view (mm) 340 × 340 340 × 340 340 × 340 340 × 340 340 × 340
Matrix 512 × 512 512 × 512 512 × 512 512 × 512 512 × 512
Section thickness (mm) 4–6 4–6 4–6 4–6 4–6
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patients with pseudotumors became symptomatic was
examined, and the growth rate of pseudotumors was
determined from follow-up MRIs. The serum cobalt and
chromium ion levels were measured closest to the date
of the MRI in 38 patients after unilateral THA (11
symptomatic and 27 asymptomatic patients). Cobalt
levels were assayed using Inductively Coupled Plasma
Mass Spectrometry (Perkin-Elmer SCIEX Elan 6100 DRC
ICPMS system; Perkin-Elmer Instruments, Norwalk, CT)
at Mayo Medical Laboratories (Rochester, MN), and
chromium levels were assayed using a graphite furnace
atomic absorption spectrometer (Z-5700; Hitachi Ltd.,
Tokyo, Japan) with polarization-Zeeman absorption at
Mitsubishi Chemistry Medience Co., Ltd. (Tokyo, Japan).
Detection limits for each ion were 0.2 μg/L [16].
This study was approved by the local institutional re-
view board, and all patients provided their informed
consent.
Statistical analysis
The Mann-Whitney U test was used to compare age,
BMI, femoral head diameter, acetabular cup inclination
and anteversion angles, time of MRI screening, pseudo-
tumor size, and serum cobalt and chromium ion levels
between symptomatic and asymptomatic patients. The
chi-squared test and Fisher’s exact test were used to
compare sex, position of pseudotumors, pseudotumor
type, and changes of pseudotumor size between the
groups. Multiple regression analysis was also performed.
Statistical significance was set at P < 0.05. Statistical ana-
lysis was performed using SPSS version 22 (SPSS, Inc,
Chicago, IL).
Results
The mean BMI was 25.4 kg/m2 in symptomatic patients
and 23.4 kg/m2 in asymptomatic patients; higher BMI
was associated with symptoms (P = 0.036, Table 2).
Symptomatic pseudotumors were significantly larger
(three-fold) than asymptomatic pseudotumors (P = 0.003,
Table 2). Pseudotumors located in the anterior position
were associated with symptoms (P = 0.032, Table 2), as
were mixed solid cystic and solid type pseudotumors
(P = 0.007, Table 2). Other factors were not signifi-
cantly different between the groups (Table 2). The
growth rate of asymptomatic pseudotumors was 132
± 502 mm2/year. On multivariate analysis, a signifi-
cant difference was seen only in size (R2 = 0.298, P =
0.031). BMI (P = 0.100), position (P = 0.116), and type
(P = 0.161) showed no significant differences on multi-
variate analysis. No asymptomatic patients with pseudotu-
mors became symptomatic during the MRI follow-up
period.
Discussion
Pseudotumors following metal-on-metal hip arthroplasty
are an important problem. Early and accurate diagnosis
of a pseudotumor is crucial to plan further management
of this potentially devastating complication because late
revision surgeries can have poor outcomes [17, 18].
However, previous longitudinal studies demonstrated
disappearance of pseudotumors [19–21]. We confirmed
that pseudotumors frequently change in size [22] on
longitudinal assessment with MRI after metal-on-metal
THA. Some patients with pseudotumors following
metal-on-metal arthroplasty have severe soft tissue dam-
age resulting in early failure. In contrast, some patients
Fig. 1 Measurement of pseudotumor size on a magnetic resonance
image by manually outlining the greatest size of the mass using
computer software
Fig. 2 Magnetic resonance images (transverse short tau inversion recovery images) showing pseudotumors (arrows) of the cystic type (a) and the
mixed solid cystic type (b)
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with pseudotumors have no symptoms. Asymptomatic
pseudotumors have been reported to occur in 27 to 73 %
of cases (Table 3) [2, 7, 8, 10]. It is desirable to determine
the characteristics of symptomatic pseudotumors.
Chang et al. [3, 23] reported that pseudotumor size
was not associated with symptoms. However, other stud-
ies [2, 7] demonstrated larger pseudotumors in symp-
tomatic patients, similar to the present study’s finding.
Hart et al. [10] confirmed that the presence of a fluid-
filled lesion (cystic type) visible on MRI had less clinical
importance, but they were concerned about solid
pseudotumors. Hauptfleisch et al. [24] reported that
predominantly solid (mixed type) pseudotumors were
associated with a higher likelihood of symptoms than
cystic pseudotumors. The present results support these
findings. In terms of metal ion concentrations, a recent
study by Sutphen et al. [8] demonstrated that elevated
serum cobalt levels might be associated with symptoms.
However, the present study, as well as the study by
Chang et al. [23], showed no significant correlation with
symptoms.
Guidelines recommending follow-up of asymptomatic
patients undergoing metal-on-metal hip arthroplasty
have already been published [25]; however, the indica-
tions for operative revision have yet to be established. In
our institution, revision is recommended for patients
with painful hips with pseudotumors.
Pseudotumors observed in asymptomatic patients
could eventually become symptomatic [23]. One of
the strengths of this study was that the follow-up
study of asymptomatic patients with pseudotumors
was observed, and no asymptomatic patients with pseudo-
tumors became symptomatic during the MRI follow-up
period.
This study has some limitations. First, a small number
of patients was studied. Second, the follow-up period
was short. A longer follow-up study will be necessary.
Third, there is no standardized definition of pseudotu-
mor in the literature. It is likely that, in some patients
with cystic pseudotumor, its presence is not a result of
an abnormal tissue reaction, but rather fluid accumula-
tion [22].
Conclusions
Higher BMI, larger pseudotumor size, pseudotumors in
the anterior position, and mixed solid cystic and solid
type of pseudotumors were predictors of symptoms on
univariate analyses. For these patients, longer follow-up
studies are required. However, larger size was the only
significant factor for symptoms on multivariate analysis,
and our first hypothesis was verified. If asymptomatic
patients with pseudotumors are asymptomatic at follow-
up MRI, especially with pseudotumors small in size in
the posterolateral position, and of cystic type, further
MRI follow-up may not be indicated because these
patients have less chance to become symptomatic.
Asymptomatic pseudotumors with small in size in the
posterolateral position, and of cystic type could be
specific factors not to become symptomatic. And our
second hypothesis was verified.
Table 2 Risk factors associated with symptomatic pseudotumors
Symptomatic Asymptomatic P
Sex
Female 15 34 0.154
Male 1 12
Age (years)a 63.1 64.1 0.803
BMI (kg/m2)a 25.4 23.4 0.036
Head diameter (mm)a 42.6 41.7 0.454
Cup inclination (°)a 45.2 43.5 0.790
Cup anteversion (°)a 14.1 13.3 0.494
Time of MRI screening (months)a 45.7 49.7 0.359
Pseudotumor size (mm2)a 1812 642 0.003
Position of pseudotumor
Anterior 10 13 0.019
Posterolateral 6 33
Pseudotumor type
Cystic 4 31 0.007
Mixed cystic solid and solid 12 15
Change of pseudotumor size
Decreased 2 6 0.083
Increased 4 8
No change 0 13
Cobalt level (μg/L)a 11.7 8.8 0.176
Chromium level (μg/L)a 10.3 6.2 0.171
amean
Table 3 Prevalence of symptoms with pseudotumors and associated factors
Authors n Symptomatic (%) Asymptomatic (%) Factor associated with symptoms
Hart et al. [10] 34 17 (50) 17 (50)
Sutphen et al. [8] 70 31 (44) 39 (56) Elevated serum cobalt level
Bisschop et al. [2] 40 11 (28) 29 (73) Larger pseudotumors
Nawabi et al. [7] 55 40 (73) 15 (27) Larger pseudotumors
Current study 62 16 (26) 46 (74) Larger pseudotumors
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